Orthocell Ltd (ASX:OCC, OTC:ORHHF) has posted record quarterly revenue of A$2.73 million for the June 2025 quarter, up 22.8% on the prior March quarter, driven by accelerating sales of its flagship nerve repair product, Remplir™, in Australia, ahead of expected uptake in the United States.
This record marks the company’s fifth consecutive record-breaking result.
Notably, the June quarter result does not yet reflect contributions from US Remplir sales, which are set to ramp up in the first half of FY26. A strong balance sheet with ~A$28.5 million cash and no debt places Orthocell in a solid position to scale its commercial footprint globally.
Orthocell’s record performance reflects increasing adoption of Remplir™ by more than 200 surgeons across over 165 Australian hospitals. The June quarter result maintains a compound quarterly growth rate (CQGR) of 9.5% over the past three years.
Surgeons are reportedly attracted to Remplir’s consistent and superior clinical outcomes, reinforcing its value as a nerve regeneration solution. Demand for the product remains robust, contributing to the A$2.73 million revenue figure achieved without US sales included.
“Achieving a record of $2.73 million in revenue for the June quarter reflects the continued strong market response to our market leading products Striate and Remplir. This outstanding result is driven by growing demand from surgeons in our existing markets and lays a solid foundation for our US expansion which we expect to ramp up in the first half of FY26,” Orthocell CEO and managing director Paul Anderson said.
Early US momentum supports upcoming scale-up
Orthocell is progressing toward a full-scale rollout of Remplir™ in the United States. The company recently marked a major milestone with the first surgical use of the product in the US market. A network of 14 specialist nerve distributors is expected to support the expansion into 25 US states, positioning Orthocell to access a market estimated at US$1.6 billion.
Commercial traction in the US is forecast to accelerate throughout FY26 as awareness and surgical experience grow.
“We’re seeing our commercialisation strategy in Australia starting to bear fruit and we are confident this will be replicated on a much larger scale in the US. With our highly experienced US distributors appointed and our first surgical use completed after achieving FDA clearance, we are well-positioned to accelerate growth in the US$1.6 billion nerve repair market over the coming months,” Anderson said.
Market potential backed by clinical validation
Remplir™ is a collagen wrap designed for use in peripheral nerve repair, with clinical data indicating improved regenerative outcomes over standard suture techniques. This includes faster return of function and higher-quality nerve restoration.
Globally, Orthocell is targeting a nerve repair market estimated at more than US$3.5 billion, with approximately 2 million procedures performed annually across key markets including the United States, the European Union, Australia and Asia.
With no debt and about A$28.5 million in cash reserves, the company is well-capitalised to drive product uptake and revenue growth in both established and new territories. The company’s commercial strategy is expected to continue delivering results as it scales up Remplir™ distribution and develops its broader regenerative medicine portfolio.
Investors will have the opportunity to hear directly from Orthocell’s executive team during a webinar scheduled for Wednesday, July 2, at 10 am WST/12 pm EST.